Success Metrics

Active Trials
9(90%)

Phase Distribution

Ph phase_2
3
30%
Ph phase_3
2
20%
Ph phase_1
5
50%

Phase Distribution

5

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

10

all time

Status Distribution
Active(10)

Detailed Status

Recruiting6
Active, not recruiting3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
9
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 23 (30.0%)
Phase 32 (20.0%)

Trials by Status

recruiting660%
active_not_recruiting330%
not_yet_recruiting110%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT06422806Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Recruiting
NCT04616534Phase 1

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Active Not Recruiting
NCT05372640Phase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Recruiting
NCT02981628Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT05327010Phase 2

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Recruiting
NCT05687110Phase 1

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Recruiting
NCT07619521Phase 1

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

Not Yet Recruiting
NCT03939897Phase 1

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Active Not Recruiting
NCT06179303Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Recruiting
NCT05646316Phase 3

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

Recruiting

All 10 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
10